Emanuela Ferraro

Hematology Oncology

11100 Euclid Ave
Cleveland, OH 44106

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 42 publications

Oral selective estrogen receptor degraders (SERDs) for the treatment of hormone receptor-positive, HER2-negative breast cancer title.

Oral selective estrogen receptor degraders (SERDs) for the treatment of hormone receptor-positive, HER2-negative breast cancer title.

Journal: Expert opinion on pharmacotherapy

Published: May 22, 2026

Treatment of breast cancer brain metastases in the era of novel drugs.

Treatment of breast cancer brain metastases in the era of novel drugs.

Journal: Cancer treatment reviews

Published: April 07, 2026

Adjuvant dual HER2 blockade along the HER2-ER axis in APHINITY.

Adjuvant dual HER2 blockade along the HER2-ER axis in APHINITY.

Journal: Journal of the National Cancer Institute

Published: April 04, 2026

Harnessing Vaccines in the Treatment of Solid Tumors: Advances, Challenges, and Future Directions.

Harnessing Vaccines in the Treatment of Solid Tumors: Advances, Challenges, and Future Directions.

Journal: Vaccines

Published: December 19, 2025

Neoadjuvant Chemotherapy for Nonmetastatic Breast Cancer: How Response Impacts Locoregional and Adjuvant Systemic Therapy Decision Making.

Neoadjuvant Chemotherapy for Nonmetastatic Breast Cancer: How Response Impacts Locoregional and Adjuvant Systemic Therapy Decision Making.

Journal: Hematology/oncology clinics of North America

Published: November 12, 2025

Monitoring of circulating tumor DNA in patients with stage II-III breast cancer treated with neoadjuvant chemotherapy.

Monitoring of circulating tumor DNA in patients with stage II-III breast cancer treated with neoadjuvant chemotherapy.

Journal: NPJ breast cancer

Published: July 04, 2025

Sequential Antibody-Drug Conjugate Therapy in Patients With Metastatic Breast Cancer Treated With Sacituzumab Govitecan and Trastuzumab Deruxtecan.

Sequential Antibody-Drug Conjugate Therapy in Patients With Metastatic Breast Cancer Treated With Sacituzumab Govitecan and Trastuzumab Deruxtecan.

Journal: JCO precision oncology

Published: May 29, 2025

RSC4All as a machine learning nomogram to predict RSClin™ results in HR+/HER2- node-negative early breast cancer.

RSC4All as a machine learning nomogram to predict RSClin™ results in HR+/HER2- node-negative early breast cancer.

Journal: ESMO open

Published: March 20, 2025

Survival Among Patients With ERBB2-Positive Metastatic Breast Cancer and Central Nervous System Disease.

Survival Among Patients With ERBB2-Positive Metastatic Breast Cancer and Central Nervous System Disease.

Journal: JAMA network open

Published: January 31, 2025

Tumor suppressor heterozygosity and homologous recombination deficiency mediate resistance to front-line therapy in breast cancer.

Tumor suppressor heterozygosity and homologous recombination deficiency mediate resistance to front-line therapy in breast cancer.

Journal: bioRxiv : the preprint server for biology

Published: September 10, 2024

Effect of age on safety and efficacy of novel cancer drugs investigated in early-phase clinical trials.

Effect of age on safety and efficacy of novel cancer drugs investigated in early-phase clinical trials.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 03, 2024

Homologous recombination deficiency and hemizygosity drive resistance in breast cancer.

Homologous recombination deficiency and hemizygosity drive resistance in breast cancer.

Journal: Nature

Published: April 03, 2024

Showing 1-12 of 42

Last Updated: 09/26/2026